TYPE 1 DIABETES
GOALS:
To salvage the pancreas before autoimmune destruction of the pancreatic beta cells which make insulin
CRITERIA:
Candidates for AAT therapy must demonstrate measurable C-peptide levels. Patients with IgA deficiency or hypersensitivity to blood products are ineligible.
DIAGNOSTIC TESTING:
Blood testing & stool microbiome testing
THERAPIES:
- Alpha Anti-trypsin (AAT)
- Artemesinin IV
- Microbiome Repair strategies
TYPE 1
DIABETES
PROGRAM
Type 1 diabetes happens when
your immune system destroys
cells in your pancreas that
make insulin.
We are initiating our work using alpha anti-trypsin (AAT) therapy to reverse the pancreatic inflammation that is the cause of pancreatic beta cell failure in Type 1 Diabetes. Alpha Anti-trypsin is obtained from plasma; recombinant versions are available commercially and are used to treat people with hereditary AAT deficiency. Recent research (http://www.diabetes.co.uk/news/2014/apr/anti-inflammatory-protein-shows-promise-for-treating-type-1-diabetes-94234088.html) indicates that in both human and animal models, AAT reverses the inflammation that leads to beta cell (the cells that make insulin) destruction in autoimmune diabetes (Type 1). So far we have encouraging results, and look forward to being of service to children with Type 1 diabetes.